Gastrodin prevents cognitive decline related to cardiopulmonary bypass

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN47168298

Enrollment

200

Registered

2006-04-25

Start date

2006-03-01

Completion date

Unknown

Last updated

2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurocognitive decline related to CPB Nervous System Diseases Neurocognitive decline

Interventions

Patients are randomized to receive either one the following interventions: 1. Gastrodin (40 mg/kg in 50 ml saline) will be injected intravenously with a pump within 45 minutes after in

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients (18 to 65 years) that have undergone mitral valve replacement surgery

Exclusion criteria

Exclusion criteria: 1. Patients who have thrombosis in left atrium 2. A history of symptomatic cerebrovascular disease 3. Diabetes 4. Psychiatric illness 5. Renal disease or active liver disease 6. Less than a seven-grade education or those who cannot read will be excluded

Design outcomes

Primary

Measure	Time frame
Neurocognitive function	—

Secondary

Measure	Time frame
Safety of gastrodin	—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026